ReviewClinical pharmacokinetics2002
Virus-based gene delivery systems.
Review in Clinical pharmacokinetics, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 83 citations in OpenAlex.
- Microfluidic Nanoparticle Separation for Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Cell-based carrier for targeted hitchhiking delivery.Drug delivery and translational research · 2022Review
- Brevinin-2R-linked polyethylenimine as a promising hybrid nano-gene-delivery vector.Iranian journal of basic medical sciences · 2019Article
- Real-Time Assembly of Viruslike Nucleocapsids Elucidated at the Single-Particle Level.Nano letters · 2019Article
- In vivo methods for acute modulation of gene expression in the central nervous system.Progress in neurobiology · 2018Review
- Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study.AAPS PharmSciTech · 2014Article
- Gene delivery from supercharged coiled-coil protein and cationic lipid hybrid complex.Biomaterials · 2014Article
- Durable expression of minicircle DNA-liposome-delivered androgen receptor cDNA in mice with hepatocellular carcinoma.BioMed research international · 2014Article
- Defining functional gene-circuit interfaces in the mouse nervous system.Genes, brain, and behavior · 2014Review
- Gene therapy approaches for lysosomal storage disease: next-generation treatment.Human gene therapy · 2012Review
- Extension of the PNA world by functionalized PNA monomers eligible candidates for inverse Diels Alder Click Chemistry.International journal of medical sciences · 2010Article
- DNA as therapeutics; an update.Indian journal of pharmaceutical sciences · 2009Article
- Ligand-directed cancer gene therapy to angiogenic vasculature.Advances in genetics · 2009Review
- Nucleofection: a new method for cutaneous gene transfer?Journal of biomedicine & biotechnology · 2006Article
- DNA-based therapeutics and DNA delivery systems: a comprehensive review.The AAPS journal · 2005Review
- Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide.Gene therapy · 2004Article
- A nonviral carrier for targeted gene delivery to tumor cells.Cancer gene therapy · 2004Article
- Dextran-spermine polycation: an efficient nonviral vector for in vitro and in vivo gene transfection.Gene therapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Within the past decade, gene therapy strategies have come to the forefront of novel therapeutics. Tremendous advances in vector technology along with deeper understandings of vector biology and the molecular mechanisms of disease have significantly advanced the field of human gene therapy. This manuscript will discuss the viral-based subset of current gene transfer vectors. In particular, the most established viral vectors to date, including parvovirus, adenovirus, retrovirus, lentivirus, and herpesvirus-based vectors, are described, as well as the current innovative improvements being made to each. From past experience, it has become evident that in addition to optimising the vectors in terms of transgene expression, minimising vector-related immunology, and vector production, methods of vector delivery resulting in optimum vector transduction of target cells need to be established. This review will also illustrate several current improved physical delivery systems for optimal vector administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.